This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Share
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
CROCS Turns OT Cyber Policy Into Action
Air Force tracks a 100-point OT cyber plan, convenes 100 experts monthly and pushes bases to rehearse operations through cyber disruptions.
13m watch -
IHS is Positioning Cybersecurity as Patient Safety
IHS CISO Benjamin Koshy explains why cybersecurity is critical to patient safety and how the agency secures care delivery in remote areas.
7m watch -
DLA CIO: Securing AI Pipelines Is Now a Core Mission
With small vendors comprising most of its supplier base, Roberts says stronger oversight and zero-trust controls are critical to counter cyber threats.
6m watch -
How to Thrive in Cybersecurity Without Burning Out
Explore mental health in cybersecurity including imposter syndrome, burnout, boundaries and building a sustainable career in high-pressure tech environments.
34m watch
